Inhibition of prolactin release by serotonin antagonists in hyperprolactinemic subjects.
Metergoline (4 mg) and methysergide (3 mg), two serotonin antagonists known to inhibit prolactin secretion in normal subjects, and the dopaminergic agonist, bromocriptine (2.5 mg) were orally administered in hyperprolactinemic patients. Mean serum prolactin concentration was significantly decreased between 120 and 240 min following the ingestion of all three drugs in comparison with a placebo; a consistent reduction to below 50% of basal values occurred in 10 of 14 patients after metergoline, in 5 of 10 after methysergide, and in 11 of 14 after bromocriptine administration. These data indicate that serotonin antagonists may acutely lower serum prolactin levels in hyperprolactinemic patients similarly to bromocriptine, though their mechanism of action is most likely different.
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D004873:Ergolines / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008711:Metergoline / Q000494:pharmacology*; D008784:Methysergide / Q000494:pharmacology* / Q000627:therapeutic use; D010900:Pituitary Diseases / Q000188:drug therapy / Q000378:metabolism*; D011388:Prolactin / Q000097:blood / Q000378:metabolism / Q000502:physiology*
D004873:Ergolines; D008711:Metergoline; D001971:Bromocriptine; D011388:Prolactin; D008784:Methysergide